145218-19-5

Basic information

• Product Name: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)
• Synonyms: Pyridine, 5-bromo-2-(bromomethyl)- (9CI);Pyridine, 5-broMo-2-(broMoMethyl)-;5-Bromo-2-(bromomethyl)
• CAS NO: 145218-19-5
• Molecular Formula: C₆H₅Br₂N
• Molecular Weight: 250.9186
• Product Categories: PYRIDINE
• Mol File: 145218-19-5.mol

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 109℃
• Appearance: /
• Density: 1.955
• Vapor Pressure: 0.025mmHg at 25°C
• Refractive Index: 1.613
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.08±0.22(Predicted)
• CAS DataBase Reference: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(145218-19-5)
• EPA Substance Registry System: Pyridine, 5-bromo-2-(bromomethyl)- (9CI)(145218-19-5)

Safety Data

• Hazardous Substances Data: 145218-19-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Pyridine, 5-bromo-2-(bromomethyl)(9CI) is utilized as a building block in organic synthesis for the construction of a variety of chemical compounds. Its unique structure allows for the creation of diverse molecules with potential applications across different fields.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Pyridine, 5-bromo-2-(bromomethyl)(9CI) is employed as an intermediate for the synthesis of drugs and other bioactive molecules. Its presence in the synthesis process can contribute to the development of new medications with improved therapeutic properties.
Used in Chemical Reactions:
Pyridine, 5-bromo-2-(bromomethyl)(9CI) is recognized for its potential as a reagent in chemical reactions. Its reactivity enables it to participate in various chemical processes, facilitating the formation of new compounds and contributing to advancements in chemical research and development.
Used in Research and Development:
Due to its importance in the development of new chemical compounds, Pyridine, 5-bromo-2-(bromomethyl)(9CI) is also used in research and development settings. Scientists and researchers leverage its properties to explore new avenues in chemical synthesis and to innovate in the creation of novel molecules with specific applications.

InChI:InChI=1/C6H5Br2N/c7-3-6-2-1-5(8)4-9-6/h1-2,4H,3H2

Upstream product

• 97483-77-7 2-Cyano-5-bromopyridine 
• 31181-90-5 5-bromo-pyridine-2-carbaldehyde 
• 88139-91-7 (5-bromopyridin-2-yl)methanol 
• 380893-61-8 (5-bromopyridin-2-yl)methyl methanesulfonate 
• 3430-13-5 5-bromo-2-methylpyridine 
• 792187-67-8 5-(bromomethyl)-2-methylpyridine 

Downstream Products

• 168823-76-5 5-bromo-2-(chloromethyl)pyridine 
• 1419605-01-8 N-(diphenylmethylene)-6-(methylsulfonylmethyl)pyridin-3-amine 
• 1419605-05-2 phenyl 6-(methylsulfonylmethyl)pyridin-3-ylcarbamate 
• 1419605-07-4 1-((1-(3-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)methyl)-3-(6-(methylsulfonylmethyl)pyridin-3-yl)urea 
• 1180132-76-6 6-((4-methylpiperazin-1-yl)methyl)pyridin-3-amine 

Relevant articles and documents

COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF

A compound of formula (I), a preparation method therefor, a pharmaceutical composition containing a derivative thereof, and the therapeutic uses thereof, especially inhibiting PGE2/EP4 signalling transduction and the uses thereof for treating cancer, acute or chronic pain, migraine, osteoarthritis, rheumatoid arthritis, gout, bursitis, ankylosing spondylitis, primary dysmenorrhea, tumour or arteriosclerosis.

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

COMPOUNDS, COMPOSITIONS, AND METHODS OF USE

Described herein are compounds that act as CYP46A1 inhibitors, compositions comprising these compounds, and methods of their use into treating neurodegenerative diseases and the like, or a pharmaceutically active salt thereof. The present invention relates to compounds represented by the formula wherein each symbol is as defined in the specification, or a pharmaceutically active salt thereof.

PqsR INVERSE AGONISTS

The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.

5-(PYRIMIDIN-4-YL)-2-(PYRROLIDIN-1-YL)NICOTINONITRILE COMPOUNDS AS IKKE, TBK1 AND/OR SIK2 KINASES INHIBITORS

The invention provides compounds of formula (I) wherein R is ?CH3 or ?CH2CH3 and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of diseases or disorders mediated by IKKE, TBK1 and/or SIK2 mechanisms in a subject, for example cancer and inflammatory and tissue repair disorders. The invention also provides uses of the compounds of formula (I) and compositions containing them. (Formula (I))

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes

We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analo

BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to novel spirocyclic piperidines according to Formula (I) which are inhibitors of fatty acid synthase (FAS), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

SUBSTITUTED CYCLOPROPYL COMPOUNDS

Substituted cyclopropyl piperidinyl compounds and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-1 19. Pharmaceutical compositions and methods of treatment are also included.